Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Isarna Therapeutics Enters into a Strategic Manufacturing Agreement with Sanofi

Published: Friday, January 10, 2014
Last Updated: Friday, January 10, 2014
Bookmark and Share
Sanofi will manufacture clinical- and commercial-grade antisense oligonucleotide (ASO) compounds for Isarna.

Isarna Therapeutics GmbH has announced that it has signed a strategic manufacturing agreement with Sanofi under which Sanofi will manufacture clinical- and commercial-grade antisense oligonucleotide (ASO) compounds for Isarna, enabling Isarna to advance its promising next generation ASOs rapidly into clinical trials. Financial details of the agreement have not been disclosed.

“At Isarna, we are convinced that the best possible manufacturing is critical as we seek to maintain an accelerated timeline for product development,” explained Dr. Philippe Calais, CEO of Isarna Therapeutics.

Dr. Calais continued, “Having Sanofi as our partner for the production of these exciting new immunotherapy compounds is a firm step forward in the development of the company and is consistent with our strategy to establish key relationships with leaders in the industry.”

As per the agreement, Sanofi’s Industrial Affairs division will act as Isarna Therapeutics’ contract manufacturing organization. Sanofi will scale-up and validate the production of ASOs and supply future commercial batches.

Isarna will benefit from Sanofi’s Commercial and External Partnership (CEPiA)’s organization, the commercial branch of Sanofi’s Industrial Affairs activities, which brings strong GMP manufacturing expertise within the field of ASOs.

The manufacturing site of Frankfurt, Germany, which will manufacture Isarna Therapeutics’ next generation ASOs, is FDA, EMEA and PMDA approved and has all the capabilities to support the registration of the compounds.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Isarna Therapeutics Raises €5.5 Million
Elizabeth Czerepak joins Company’s management team as Chief Financial Officer and Chief Business Officer.
Friday, April 25, 2014
Scientific News
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!